Analysts Set Price Target for Fate Therapeutics at $3.92

Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus recommendation of “Hold” from analysts monitoring the company. According to MarketBeat, among the nine analysts currently covering Fate Therapeutics, one has issued a sell rating, five maintain a hold recommendation, and three have rated the stock as a buy. The average target price for the stock over the next 12 months stands at approximately $3.92.

Several brokerage firms have recently updated their assessments of Fate Therapeutics. On November 4, Cantor Fitzgerald reaffirmed a “neutral” rating, while Needham & Company LLC reiterated a “hold” rating on October 27. Conversely, Weiss Ratings assigned a “sell (e+)” rating on October 8. Notably, Wedbush upgraded Fate Therapeutics from a “neutral” to an “outperform” rating and adjusted their price target from $5.00 to $7.00 in their report on October 27. In contrast, Wall Street Zen downgraded the stock from a “hold” to a “sell” rating on November 8.

Current Stock Performance and Financial Overview

As of November 27, Fate Therapeutics shares opened at $1.05. The company has a 50-day simple moving average of $1.05 and a 200-day moving average of $1.13. Over the past year, the stock has experienced a low of $0.66 and a high of $1.94. Fate Therapeutics currently holds a market capitalization of $121.12 million, alongside a price-to-earnings ratio of -0.80 and a beta of 2.22.

In its latest quarterly earnings report released on November 13, the company reported earnings per share of ($0.27), surpassing the consensus estimate of ($0.29) by $0.02. The firm generated revenues of $1.74 million, slightly exceeding analyst projections of $1.63 million. Despite these figures, Fate Therapeutics recorded a negative net margin of 2,187.11% and a negative return on equity of 51.28%. Analysts forecast an average earnings per share of (–1.63) for the current fiscal year.

About Fate Therapeutics

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing first-in-class cellular immunotherapies aimed at treating cancer and immune disorders. The company utilizes its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf natural killer (NK) and T-cell products that aim to address the limitations associated with donor-derived therapies.

Fate’s research is focused on delivering therapies that offer consistent quality and increased potency while ensuring scalable manufacturing for broader patient accessibility. The company’s pipeline features multiple iPSC-derived cell therapy candidates currently in active clinical development.

Investors and interested parties can stay informed about Fate Therapeutics and its stock performance through various financial news platforms.